Mergers and Acquisitions

The CDMO launched earlier this year at the CPHI conference in Milan.

The merger is comprised of Stelis Sciences, Strides and Steriscience. The merger will see the successful integration of the biologics CDMO offered by Stelis in addition to Strides’s soft gelatine business and SterisSciences’ complex injectables.

The businesses combined to create a specialist CDMO in order to address increasing demand for drug biologics substances and drug-device combinations. With the introduction of the BIOSECURE act, the company claims it is uniquely positioned to assist customers as the market demands for increased supply chain diversity. OneSource is India’s first specialty pharma pure-play CDMO business.

CEO of OneSource, Neeraj Sharma stated, “Our vision is to blend the expertise of global CDMO giants with the agility and service levels of a challenger, all supported by our unwavering commitment to bring the most efficient and quality products to our partners.”

The company’s solutions span across platforms and therapeutic modalities, including drug-device combinations, biologics, oral technologies and complex injectables, and is predicted to reach $400m in revenue in the course of five years.

OneSource’s flagship facility in Bangalore will have the capability to produce biologics drug substances, as well as other drugs in the same premises; one of the few global facilities to have enough capacity to complete this task.